Abstract

Background: Biologic drugs, especially anti TNF-α drugs, are revolutionary in the treatment of Spondyloarthritis when the conventional DMARDs have proved ineffective. Research objective: To evaluate the effectiveness of Infliximab treatment on Spondyloarthritis patients. Materials and method: Longitudinal follow-up study with Infliximab treatment on 27 patients with Spondyloarthritis. Results: The effectiveness of Infliximab on patients with Spondyloarthritis is demonstrated by clinical indicators; inflammatory markers: CRP , ESR in the first hour and the disease activity level according to ASDAS-CRP and ASDAS-ESR in the first hour at the time of T2, T6 compared to T0 were statistically significant (p < 0.05) ). After excluding the data of 2 patients with flare at T14, all the above-mentioned indicators improved, the difference was statistically significant with p < 0.05. Conclusion: Infliximab is effective in improving clinical symptoms, inflammatory markers and disease activity score in patients with Spondyloarthritis.